Finnegan client Astellas Pharma US LLC filed an infringement suit June 21 in the District of New Jersey against Sagent Pharmaceuticals Inc. and Strides Arcolab Ltd., related to their recent ANDA application seeking approval to make a generic version of Adenoscan®, used as an adjunct to thallium-201 myocardial perfusion scintigraphy in the diagnosis of coronary artery disease patients who are not able to exercise adequately. Astellas is represented by Finnegan in this matter.
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.